Tradestie Institutional Equity Comparison Engine
EQ vs ACHV โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ACHV Overall Edge
ACHV Captures Institutional Edge (2โ1 Pillars ยท 5โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Achieve Life Sciences, Inc. (ACHV) driven by superior Momentum & Technical, Options & Structure while EQ counters with relative strength in Valuation. Fundamentally, EQ trades at 1.5x Forward P/E with 0.0% operating margin (-52.3% YoY revenue) versus ACHV at 35.3x Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, EQ sits in UNCLASSIFIED (100th %ile IV; Dealer Gamma Walls on Pro) against ACHV sits in BREAKOUT (23rd %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
EQ
EQ 1.5x vs ACHV 35.3x Fwd P/E
Growth & Margin Winner
Tie
Op Margin 0.0% vs 0.0% ยท YoY -52.3% vs +0.0%
Momentum & Technical Winner
ACHV
1Y +12.0% vs +43.0% ยท 52W Pos 11% vs 69%
Options & Structure Winner
ACHV
UNCLASSIFIED (100th %ile IV) vs BREAKOUT (23rd %ile IV)
EQ
NASDAQ
Equillium, Inc. Common Stock
Pharmaceutical Preparations
$1.12
+1.82% 1D
Market Cap
$90.6M
1M Return
-21.13%
1Y Return
+12.0%
Forward P/E
1.5x
Unified AI Score
48.0 / 100
HOLD
Tech 30.0
Fund 51.0
Flow 63.0
Mom 60.0
ACHV
NASDAQ
Achieve Life Sciences, Inc.
In Vitro & In Vivo Diagnostic Substances
$6.78
+0.89% 1D
Market Cap
$692.8M
1M Return
-8.5%
1Y Return
+43.04%
Forward P/E
35.3x
Unified AI Score
56.6 / 100
HOLD
Tech 66.0
Fund 58.0
Flow 57.0
Mom 58.9
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
EQ +12.0%
ACHV +43.04%
Spread: +6.58 pp (ACHV Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
EQ TTM Op. Margin: 0.0%
ACHV TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on EQ vs ACHV. Trailing 12-month operating profitability (EQ 0.0% vs ACHV 0.0%) and valuation multiples (EQ 1.5x vs ACHV 35.3x Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | EQ | ACHV | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $90.6M | $692.8M | Larger Scale | ACHV |
| Trailing P/E Ratio Valuation | 1.5x | 35.3x | Lower Multiple | EQ |
| Forward P/E Ratio Valuation | 1.5x | 35.3x | Lower Multiple | EQ |
| Revenue Growth (YoY) Growth | -52.3% | +0.0% | Higher Growth | ACHV |
| Operating Margin (TTM) Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -59.0% | -845.0% | Higher ROE | EQ |
| 52-Week Range Position Momentum | 11% ($1โ$4) | 69% ($3โ$9) | Stronger Trend | ACHV |
| Beta / 30D Volatility Risk Regime | 1.53ฮฒ ยท 93% Vol | 1.73ฮฒ ยท 62% Vol | Lower Realized Risk | ACHV |
| Unified Institutional Score Composite Signal | 48.0 / 100 (HOLD) | 56.6 / 100 (HOLD) | Higher Composite | ACHV |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full EQ vs ACHV Buy Guide
EQ
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
100th %ile
IV Regime
Extreme (>80th %ile)
ACHV
BREAKOUT
125d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
23rd %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither EQ nor ACHV registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.